Representative April McClain Delaney (D-Maryland) recently bought shares of IDEXX Laboratories, Inc. NASDAQ: IDXX. In a filing disclosed on May 02nd, the Representative disclosed that they had bought between $1,001 and $15,000 in IDEXX Laboratories stock on April 4th.
Representative April McClain Delaney also recently made the following trade(s):
- Sold $1,001 - $15,000 in shares of Toro NYSE: TTC on 4/29/2025.
- Purchased $1,001 - $15,000 in shares of Bio-Techne NASDAQ: TECH on 4/29/2025.
- Sold $1,001 - $15,000 in shares of Dayforce NYSE: DAY on 4/28/2025.
- Purchased $1,001 - $15,000 in shares of Markel Group NYSE: MKL on 4/24/2025.
- Sold $1,001 - $15,000 in shares of A. O. Smith NYSE: AOS on 4/16/2025.
- Sold $1,001 - $15,000 in shares of A. O. Smith NYSE: AOS on 4/10/2025.
- Sold $1,001 - $15,000 in shares of Toro NYSE: TTC on 4/10/2025.
- Purchased $1,001 - $15,000 in shares of Bio-Techne NASDAQ: TECH on 4/9/2025.
- Purchased $1,001 - $15,000 in shares of IDEXX Laboratories NASDAQ: IDXX on 4/9/2025.
- Purchased $1,001 - $15,000 in shares of Markel Group NYSE: MKL on 4/9/2025.
IDEXX Laboratories Trading Up 0.7 %
NASDAQ IDXX opened at $475.07 on Tuesday. The company has a debt-to-equity ratio of 0.28, a quick ratio of 0.95 and a current ratio of 1.31. IDEXX Laboratories, Inc. has a one year low of $356.14 and a one year high of $548.88. The firm's fifty day moving average is $419.61 and its two-hundred day moving average is $428.18. The firm has a market cap of $38.50 billion, a PE ratio of 44.52, a P/E/G ratio of 3.41 and a beta of 1.50.
IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The company reported $2.96 earnings per share for the quarter, topping the consensus estimate of $2.93 by $0.03. The firm had revenue of $998.43 million during the quarter, compared to the consensus estimate of $998.25 million. IDEXX Laboratories had a return on equity of 55.82% and a net margin of 22.78%. The company's revenue for the quarter was up 3.6% on a year-over-year basis. During the same period last year, the company earned $2.71 earnings per share. Analysts expect that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current year.
Institutional Trading of IDEXX Laboratories
Institutional investors have recently bought and sold shares of the company. MorganRosel Wealth Management LLC purchased a new stake in shares of IDEXX Laboratories in the 1st quarter worth about $26,000. Hurley Capital LLC acquired a new position in IDEXX Laboratories during the fourth quarter worth about $29,000. Rialto Wealth Management LLC acquired a new position in IDEXX Laboratories during the fourth quarter worth about $30,000. Retirement Wealth Solutions LLC purchased a new stake in shares of IDEXX Laboratories in the fourth quarter valued at about $31,000. Finally, Colonial Trust Co SC grew its position in shares of IDEXX Laboratories by 84.8% in the fourth quarter. Colonial Trust Co SC now owns 85 shares of the company's stock valued at $35,000 after purchasing an additional 39 shares during the last quarter. 87.84% of the stock is currently owned by hedge funds and other institutional investors.
Analyst Upgrades and Downgrades
A number of brokerages have recently issued reports on IDXX. Stifel Nicolaus dropped their price target on shares of IDEXX Laboratories from $450.00 to $420.00 and set a "hold" rating on the stock in a research note on Monday, April 14th. Piper Sandler boosted their target price on IDEXX Laboratories from $435.00 to $510.00 and gave the stock a "neutral" rating in a research report on Monday, February 10th. StockNews.com downgraded IDEXX Laboratories from a "buy" rating to a "hold" rating in a research note on Saturday, April 12th. Morgan Stanley lifted their price target on IDEXX Laboratories from $548.00 to $558.00 and gave the company an "overweight" rating in a research note on Monday. Finally, Bank of America increased their price objective on IDEXX Laboratories from $475.00 to $535.00 and gave the stock a "neutral" rating in a research report on Tuesday, February 4th. Four research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, IDEXX Laboratories has a consensus rating of "Moderate Buy" and an average target price of $524.75.
Read Our Latest Stock Report on IDEXX Laboratories
Insider Transactions at IDEXX Laboratories
In other news, EVP George Fennell sold 9,986 shares of the company's stock in a transaction on Monday, February 10th. The stock was sold at an average price of $462.53, for a total value of $4,618,824.58. Following the sale, the executive vice president now directly owns 8,176 shares in the company, valued at $3,781,645.28. This represents a 54.98 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director M Anne Szostak sold 3,000 shares of IDEXX Laboratories stock in a transaction dated Friday, February 7th. The stock was sold at an average price of $465.94, for a total value of $1,397,820.00. Following the sale, the director now owns 3,061 shares of the company's stock, valued at approximately $1,426,242.34. This represents a 49.50 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 0.98% of the company's stock.
About Representative McClain Delaney
April McClain-Delaney (Democratic Party) is a member of the U.S. House, representing Maryland's 6th Congressional District. She assumed office on January 3, 2025. Her current term ends on January 3, 2027.
McClain-Delaney (Democratic Party) is running for re-election to the U.S. House to represent Maryland's 6th Congressional District. She declared candidacy for the 2026 election.
April McClain-Delaney grew up in Buhl, Idaho, where her father was a potato farmer. She obtained her bachelor's degree in communications from Northwestern University in 1986 and her law degree from Georgetown Law Center in 1989. McClain-Delaney worked in communications law, first with the satellite firm Orion Network Systems and later as the Washington director for Common Sense Media, a nonprofit focused on technology and children. In 2022, McClain-Delaney joined the U.S. Department of Commerce under President Joe Biden (D) as deputy assistant secretary for communications and information. McClain-Delaney served on the board of the Georgetown University Law Center, the International Center for Research on Women, and the Northwestern University School of Communications.
About IDEXX Laboratories
(
Get Free Report)
IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider IDEXX Laboratories, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IDEXX Laboratories wasn't on the list.
While IDEXX Laboratories currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
